Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2023 May;11(5):1475-1484.e20.
doi: 10.1016/j.jaip.2022.12.046. Epub 2023 Jan 28.

Incidence of Anti-Drug Antibodies to Monoclonal Antibodies in Asthma: A Systematic Review and Meta-Analysis

Ming-Li Chen  1 , Tanawin Nopsopon  2 , Ayobami Akenroye  3
Affiliations
Meta-Analysis

Incidence of Anti-Drug Antibodies to Monoclonal Antibodies in Asthma: A Systematic Review and Meta-Analysis

Ming-Li Chen et al. J Allergy Clin Immunol Pract. 2023 May.

Abstract

Background: Antidrug antibodies (ADAs) may worsen the efficacy and safety of biologics. However, little is known about the incidence of ADAs associated with the 6 biologics approved for the treatment of asthma in the United States.

Objective: To elucidate the incidence of ADAs and their impact on reported clinical outcomes.

Methods: Systematic review and meta-analyses of randomized controlled trials, open-label extension studies, and nonrandomized studies of biologics in patients with asthma indexed in PubMed, Embase, and CENTRAL between January 1, 2000, and July 9, 2022, were carried out. The primary outcomes were treatment-emergent ADAs (incidence) and ADA prevalence.

Results: A total of 46 studies met the eligibility criteria. ADA incidence over follow-up was 2.91% (95% CI, 1.60-4.55) and was highest in the benralizumab studies (8.35%), with a risk ratio of 4.9 (2.69-8.92) when compared with placebo, and lowest in the omalizumab studies (0.00%). Incidence was 7.61% in the dupilumab studies, 4.39% in reslizumab, 3.63% in mepolizumab, and 1.12% in the tezepelumab studies. Incidence of neutralizing antibodies was 0.00% to 10.74% and was highest for benralizumab (7.12%). Incidence of neutralizing antibodies was higher in the benralizumab every 8 weeks (8.17%) versus every 4 weeks arms (5.81%). Results were consistent in subgroup analyses by study type and length of follow-up.

Conclusions: Approximately 2.9% of individuals in the included studies developed ADAs over study follow-up period. The incidence was highest in the benralizumab group and lowest in the omalizumab group. The subcutaneous route and longer dosing intervals were associated with higher ADA development.

Keywords: Antidrug antibodies; Asthma; Biologics; Immunogenicity; mAbs.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: The authors declare that they have no relevant conflicts of interest.

Figures

FIGURE 1.
FIGURE 1.
TE-ADAs in patients with asthma in the biologic treatment arms. *Showing results from studies in which this outcome was reported.
FIGURE 2.
FIGURE 2.
Incidence of NAbs in patients with asthma in the biologic treatment arms. *Showing results from studies in which this outcome was reported.
FIGURE 3.
FIGURE 3.
RR of (A) TE-ADAs and (B) NAbs in the treatment arms vs the placebo arm. *Showing results from studies in which this outcome was reported. Weights and between-subgroup heterogeneity test are from random-effects model (continuity correction applied to studies with 0 cells).
See this image and copyright information in PMC

References

    1. Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108:184–90. - PubMed
    1. Farne HA, Wilson A, Milan S, Banchoff E, Yang F, Powell CV. Anti-IL-5 therapies for asthma. Cochrane Database Syst Rev 2022;7:Cd010834. - PMC - PubMed
    1. Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet 2016;388:31–44. - PubMed
    1. Corren J, Parnes JR, Wang L, Mo M, Roseti SL, Griffiths JM, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med 2017;377:936–46. - PubMed
    1. Gallagher A, Edwards M, Nair P, Drew S, Vyas A, Sharma R, et al. Antiinterleukin-13 and anti-interleukin-4 agents versus placebo, anti-interleukin-5 or anti-immunoglobulin-E agents, for people with asthma. Cochrane Database Syst Rev 2021;10:Cd012929. - PMC - PubMed

Publication types

MeSH terms